B
Bull
Bull · 25%INMD
$15.83
Precio del escenario
$14.850
+0.010 (+0.07%)Al cierre
Loading chart…
- High
- 14.940
- Open
- 14.880
- VWAP
- 14.87
- Vol
- 456.67K
- Mkt Cap
- 1.53B
- Low
- 14.830
- Amount
- 6.79M
- EV/EBITDA, TTM
- 9.39
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
AI analysis of Inmode Ltd (INMD)
holdInMode Ltd is currently priced at $14.85, which is near the lower end of analyst price targets, indicating potential upside. However, the RSI is at 31.194, suggesting the stock is oversold, but the recent 5-day change is -1.39%, indicating a downward trend. The main risk is the recent acquisition bid from Steel Partners, which could create volatility depending on the outcome.
Métricas de valoración
The current forward P/E ratio for Inmode Ltd (INMD) is 11.14, compared to its 5-year average forward P/E of 13.09.
Alphio AI Price Scenarios for INMD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding INMD
Cronología de eventos
Noticias
9.508-05PRnewswireInMode Reports Stable Q2 2026 Financial Results Amid Market Challenges
9.508-05seekingalphaInMode Q2 Earnings Exceed Expectations
8.508-04NewsfilterDisruptive Opportunities in Emerging Aesthetic Market
9.507-13PRnewswireInMode to Release Q2 2026 Financial Results
9.507-13NewsfilterInMode Announces Q2 2026 Financial Results Release Date
INMD FAQ — answered by Alphio AI
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).
InMode Ltd is currently priced at $14.85, which is near the lower end of analyst price targets, indicating potential upside. However, the RSI is at 31.194, suggesting the stock is oversold, but the recent 5-day change is -1.39%, indicating a downward trend. The main risk is the recent acquisition bid from Steel Partners, which could create volatility depending on the outcome.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.